10-KPeriod: FY2010

Merck & Co., Inc. Annual Report, Year Ended Dec 31, 2010

Filed February 28, 2011For Securities:MRK

Summary

Merck & Co., Inc. (MRK) reported a significant increase in sales to $46.0 billion for the fiscal year ended December 31, 2010. This growth was primarily driven by the full-year inclusion of results from the Schering-Plough merger completed in November 2009, which integrated legacy Schering-Plough products like Remicade and Nasonex, as well as Zetia and Vytorin. The company experienced challenges including patent expirations for key products such as Cozaar/Hyzaar, leading to sales declines in those areas. Additionally, Merck incurred substantial restructuring costs totaling $1.8 billion related to the integration of Schering-Plough, aiming for significant future cost savings. The company also faced increased expenses due to U.S. healthcare reform legislation and global austerity measures impacting pricing. Merck's pipeline shows progress with new approvals like Dulera and updated indications for Gardasil. However, the company also recorded a significant impairment charge of $1.7 billion related to the vorapaxar development program. Investors should note the ongoing arbitration with Centocor regarding Remicade and Simponi rights, which could materially affect future results.

Financial Highlights

53 data points
Beta

Revenue

$45.99B

60.0% Gross Margin

Net Income

$861.00M

1.9% Net Margin

EPS (Diluted)

$0.28

Total Assets

$105.78B

Cash & Equivalents

$10.90B

Free Cash Flow

$10.82B

Financial Statements
Beta
Revenue$45.99B
Cost of Revenue$18.40B
Gross Profit$27.59B
R&D Expenses$11.11B
SG&A Expenses$13.13B
Interest Expense$715.00M
Net Income$861.00M
EPS (Basic)$0.28
EPS (Diluted)$0.28
Shares Outstanding (Basic)3K
Shares Outstanding (Diluted)3K

Key Highlights

  • 1Total sales reached $46.0 billion, a substantial increase driven by the full-year impact of the Schering-Plough merger.
  • 2Key products like Singulair, Januvia, and Isentress showed growth, while Cozaar/Hyzaar sales declined due to patent expirations.
  • 3Merck incurred $1.8 billion in restructuring costs related to the Schering-Plough integration, with expected annual savings of $2.7-$3.1 billion by 2012.
  • 4The company recorded a $1.7 billion impairment charge for the vorapaxar clinical development program.
  • 5U.S. healthcare reform legislation led to increased Medicaid rebates and other impacts, reducing revenue by approximately $170 million.
  • 6The company is awaiting a decision in an arbitration proceeding with Centocor concerning marketing rights for Remicade and Simponi, with an unfavorable outcome potentially having a material adverse effect.
  • 7Merck advanced its R&D pipeline with new drug approvals and filed applications, but also faced challenges like the vorapaxar development setback.

Frequently Asked Questions

The primary driver of Merck's sales growth in 2010 was the full-year inclusion of results from the legacy Schering-Plough products following the completion of the merger in November 2009. This integration significantly boosted overall sales.

Key risks and challenges include patent expirations for major products like Singulair and Cozaar/Hyzaar, which are expected to lead to significant sales declines. Additionally, the company incurred substantial restructuring costs due to the merger, faced impacts from U.S. healthcare reform, and is involved in critical legal and arbitration proceedings that could materially affect its financial position.

Merck is focused on growing its pipeline of new products and advancing late-stage drug candidates. The company also continues to emphasize growth from products like Januvia and Isentress, which are performing well, and is managing its portfolio to mitigate the impact of patent expiries.

The $1.7 billion impairment charge for vorapaxar indicates a significant setback in the development of this product. This resulted from clinical trial developments where safety concerns, specifically an increased risk of intracranial hemorrhage, led to study discontinuations and a reevaluation of the asset's fair value.